7 05, 2020 Elisabetta Zulato et. al., Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer Diatech Pharmacogenetics2020-11-03T15:24:44+01:00 Leggi di più